Spinocerebellar Ataxia (SCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Spinocerebellar Ataxia Pipeline Drugs Market Overview
Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Its symptoms include poor coordination, unsteady walking, change in speech, and difficulty swallowing.
The Spinocerebellar Ataxia pipeline market research report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinocerebellar Ataxia and features dormant and discontinued projects.
Spinocerebellar Ataxia Pipeline Products Market Segmentation by Targets
The key targets in the Spinocerebellar Ataxia pipeline products market are Ataxin 3, Ataxin 1, Ataxin 2, Calcium Activated Neutral Protease, Excitatory Amino Acid Transporter 2, Huntingtin, Polyadenylate Binding Protein 2, Adenosine Receptor A2a, Ataxin 10, Calcium Activated Potassium Channel, and others.
Spinocerebellar Ataxia Pipeline Products Market Analysis by Targets
For more target insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample
Spinocerebellar Ataxia Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Spinocerebellar Ataxia pipeline products market are Ataxin 3 Inhibitor, Ataxin 1 Inhibitor, Ataxin 2 Inhibitor, Calcium Activated Neutral Protease Inhibitor, Excitatory Amino Acid Transporter 2 Activator, Polyadenylate Binding Protein 2 (Poly(A) Binding Protein 2 or Nuclear PolyInhibitor, Adenosine Receptor A2a Agonist, Ataxin 10 Inhibitor, Calcium Activated Potassium Channel Activator, DNA Mismatch Repair Protein Msh3 Inhibitor, and others.
Spinocerebellar Ataxia Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample
Spinocerebellar Ataxia Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Spinocerebellar Ataxia pipeline products market are oral, intravenous, intrathecal, intraarticular, parenteral, intrauterine, and nasal.
Spinocerebellar Ataxia Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample
Spinocerebellar Ataxia Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Spinocerebellar Ataxia pipeline products market are small molecule, antisense oligonucleotide, cell therapy, gene therapy, oligonucleotide, antisense RNAi oligonucleotide, recombinant protein, and RNAi gene therapy.
Spinocerebellar Ataxia Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Spinocerebellar Ataxia pipeline products market, download a free report sample
Competitive Landscape
Some of the leading players in the Spinocerebellar Ataxia pipeline products market are Ionis Pharmaceuticals Inc, Anima Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd, Blade Therapeutics Inc, Seelos Therapeutics Inc., Steminent Biotherapeutics Inc, Annji Pharmaceutical Co Ltd, Biogen Inc, BioXcel Corp, and Celavie Biosciences LLC.
Spinocerebellar Ataxia Pipeline Products Market Analysis by Players
To know more about the leading players in the Spinocerebellar Ataxia pipeline products market, download a free report sample
Spinocerebellar Ataxia Pipeline Products Market Report Overview
Key Targets | Ataxin 3, Ataxin 1, Ataxin 2, Calcium Activated Neutral Protease, Excitatory Amino Acid Transporter 2, Huntingtin, Polyadenylate Binding Protein 2, Adenosine Receptor A2a, Ataxin 10, Calcium Activated Potassium Channel, and Others |
Key Mechanisms of Action | Ataxin 3 Inhibitor, Ataxin 1 Inhibitor, Ataxin 2 Inhibitor, Calcium Activated Neutral Protease Inhibitor, Excitatory Amino Acid Transporter 2 Activator, Polyadenylate Binding Protein 2 (Poly(A) Binding Protein 2 or Nuclear PolyInhibitor, Adenosine Receptor A2a Agonist, Ataxin 10 Inhibitor, Calcium Activated Potassium Channel Activator, DNA Mismatch Repair Protein Msh3 Inhibitor, and Others |
Key Routes of Administration | Oral, Intravenous, Intrathecal, Intraarticular, Parenteral, Intrauterine, and Nasal |
Key Molecule Type | Small Molecule, Antisense Oligonucleotide, Cell Therapy, Gene Therapy, Oligonucleotide, Antisense RNAi Oligonucleotide, Recombinant Protein, and RNAi Gene Therapy |
Leading Players | Ionis Pharmaceuticals Inc, Anima Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd, Blade Therapeutics Inc, Seelos Therapeutics Inc., Steminent Biotherapeutics Inc, Annji Pharmaceutical Co Ltd, Biogen Inc, BioXcel Corp, and Celavie Biosciences LLC |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Annji Pharmaceutical Co Ltd
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
BioXcel Corp
Blade Therapeutics Inc
Celavie Biosciences LLC
Corestem Inc
Dystrogen Therapeutics SA
Enzerna Biosciences LLC
Everfront Biotech Inc
Exicure Inc
Gene Therapy Research Institution Co Ltd
IntraBio Ltd
Ionis Pharmaceuticals Inc
Locanabio Inc
Novartis AG
PTC Therapeutics Inc
Q-State Biosciences Inc
Sclnow Biotechnology Co Ltd
Seelos Therapeutics, Inc.
Shionogi & Co Ltd
Steminent Biotherapeutics Inc
Triplet Therapeutics Inc
Vico Therapeutics BV
Vybion Inc
Wave Life Sciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Spinocerebellar Ataxia pipeline products market?
The key targets in the Spinocerebellar Ataxia pipeline products market are Ataxin 3, Ataxin 1, Ataxin 2, Calcium Activated Neutral Protease, Excitatory Amino Acid Transporter 2, Huntingtin, Polyadenylate Binding Protein 2, Adenosine Receptor A2a, Ataxin 10, Calcium Activated Potassium Channel, and others.
-
What are the key mechanisms of action in the Spinocerebellar Ataxia pipeline products market?
The key mechanisms of action in the Spinocerebellar Ataxia pipeline products market are Ataxin 3 Inhibitor, Ataxin 1 Inhibitor, Ataxin 2 Inhibitor, Calcium Activated Neutral Protease Inhibitor, Excitatory Amino Acid Transporter 2 Activator, Polyadenylate Binding Protein 2 (Poly(A) Binding Protein 2 or Nuclear PolyInhibitor, Adenosine Receptor A2a Agonist, Ataxin 10 Inhibitor, Calcium Activated Potassium Channel Activator, DNA Mismatch Repair Protein Msh3 Inhibitor, and others.
-
What are the key routes of administration in the Spinocerebellar Ataxia pipeline products market?
The key routes of administration in the Spinocerebellar Ataxia pipeline products market are oral, intravenous, intrathecal, intraarticular, parenteral, intrauterine, and nasal.
-
What are the key molecule types in the Spinocerebellar Ataxia pipeline products market?
The key molecule types in the Spinocerebellar Ataxia pipeline products market are small molecule, antisense oligonucleotide, cell therapy, gene therapy, oligonucleotide, antisense RNAi oligonucleotide, recombinant protein, and RNAi gene therapy.
-
Who are the leading players in the Spinocerebellar Ataxia pipeline products market?
The leading players in the Spinocerebellar Ataxia pipeline products market are Ionis Pharmaceuticals Inc, Anima Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd, Blade Therapeutics Inc, Seelos Therapeutics Inc., Steminent Biotherapeutics Inc, Annji Pharmaceutical Co Ltd, Biogen Inc, BioXcel Corp, and Celavie Biosciences LLC.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.